Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4566692 | 0.98 | ATM (0.63) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL21568856 | 0.92 | L3MBTL1 (0.61) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL13188548 | 0.88 | ATM (0.58) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL20693526 | 0.86 | ATM (0.56) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL12446607 | 0.86 | ATM (0.56) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL18909475 | 0.83 | ATM (0.52) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL13974287 | 0.83 | GNAI3 (0.44) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL14013013 | 0.80 | ATM (0.41) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL13220569 | 0.79 | ATM (0.59) | ATML3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL24242445 | 0.78 | ATM (0.63) | ATML3MBTL1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | ATM 1963/4885L3MBTL1 2485/4885MEN1 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.